Back to Search
PAOLA CONTE, PHD
PHD
Clinical Psychologist
NPI: 1467678961Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
4052(NJ)
Research & Publications (20)
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
PMID 19095777·Ann Oncol·2009
8-other
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
PMID 19617703·Cancer Biol Ther·2009
8-other
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
PMID 19509559·Int J Gynecol Cancer·2009
3-trial
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
PMID 19584872·Br J Cancer·2009
3-trial
Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients.
PMID 19185301·Atherosclerosis·2009
8-other
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
PMID 19221152·Ann Oncol·2009
8-other
Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa.
PMID 19424002·Transplantation·2009
8-other
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
PMID 19004567·Int J Radiat Oncol Biol Phys·2009
3-trial
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.
PMID 19608638·Oncologist·2009
6-review
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation.
PMID 19433859·Blood·2009
7-preclinical
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
PMID 18791821·Breast Cancer Res Treat·2009
3-trial
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
PMID 19660136·J Hematol Oncol·2009
5-case
Dynamics of cross polarization in solid state nuclear magnetic resonance experiments of amorphous and heterogeneous natural organic substances.
PMID 18781033·Anal Sci·2008
8-other
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
PMID 18952561·Clin Breast Cancer·2008
3-trial
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
PMID 18621618·Clin Breast Cancer·2008
3-trial
Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer.
PMID 18525313·Am J Clin Oncol·2008
5-case
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
PMID 18501066·Clin Breast Cancer·2008
4-observational
From the ICU to the ward: cross-checking of the physician's transfer report by intensive care nurses.
PMID 18461306·Intensive Care Med·2008
8-other
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
PMID 18650259·Oncologist·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 615 FRANKLIN TPKE, SUITE 1
RIDGEWOOD, NJ 07450 - Phone
- (201) 444-0090
Quick Facts
- NPI
- 1467678961
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile